High Dose Steroids in Children With Stroke (PASTA)

High Dose Steroids in Children With Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial PASTA (Paediatric Arteriopathy Steroid Aspirin) Trial

This clinical trial deals with focal cerebral arteriopathy and childhood stroke, a rare but devastating condition.

Focal cerebral arteriopathy (FCA) is an inflammatory vessel wall disease provoked by infection and there is increasing evidence that inflammatory processes play a crucial role in childhood stroke, influencing the outcome of the disease.

Analysis of existing data suggests that outcomes are improved and that there is less stroke recurrence in children treated with steroids to reduce the acute inflammatory processes. This clinical trial will be conducted in over 20 hospitals in several countries in order to investigate this.

Participants will be randomly separated into two groups. The first group will be treated with standard of care (including aspirin) combined with high dose steroids. The second group will be treated with standard of care (including aspirin) but without steroid treatment.

The objective is to investigate if children treated with a combination of high dose steroid and aspirin will have a better and quicker recovery of FCA, better clinical functional outcome, and less recurrence compared to children treated with aspirin alone.

This project has been identified by international pediatric stroke experts as the most important topic for a clinical trial in the field and is as well one of the most important research priorities identified by parents. The study results will also provide insight into the evolution of inflammatory vessel disease.

Study Overview

• Status: Recruiting
• Conditions: Paediatric Stroke
• Intervention / Treatment: Drug: Prednisolone; Drug: Methylprednisolone

Detailed Description

Background: Arterial ischemic stroke (AIS) is a rare but devastating condition affecting 2-5/100,000 children/year. Children do not recover better than adults with 2/3 suffering long term neurological, cognitive and behavioural problems. The economic cost of stroke is substantial. Arteriopathy is identified as AIS aetiology in 60-80% of previously healthy children and is the strongest predictor of recurrent events. 30-40% of these children will have a focal cerebral arteriopathy (FCA). FCA in childhood is shown to be an inflammatory vessel wall pathology provoked by infections. This encourages treatment with steroids, despite lack of evidence.

Rationale: There is increasing evidence that etiologically inflammatory processes play a crucial role in childhood stroke, and influence outcome. Retrospective analyses suggest improved outcome and less recurrence with steroid treatment. With the exception of sickle cell disease, this study will be the first randomized clinical trial in children with arterial ischemic stroke. It will provide high-level evidence for the most appropriate treatment for children with AIS due to FCA. Alignment of interventions and outcome as well as pooled analysis with the planned Focal Cerebral Arteriopathy Steroid (FOCAS) study in North America will allow pooled analysis results.This is very important in view of the marked neurological, social and economic burden of childhood AIS for patients and families. This project has been identified as the most important AIS treatment trial by a Delphi survey of international paediatric stroke experts and is one of the most important research priorities identified by parents. In addition, the study will provide insights into the pathogenesis of inflammatory vasculopathies.The objective of this trial is to show that children with first stroke event due to unilateral FCA treated with a combination of high dose steroid and aspirin will have better and quicker recovery of arteriopathy, better clinical functional outcome, and less recurrence compared to children treated with aspirin alone.

The proposed study is a prospective multicentre, parallel group, two-arm, randomized controlled, open-label clinical trial with blinded outcome assessment, comparing a high dose course of methylprednisolone / prednisolone plus standard of care with standard of care alone in children with unilateral arteriopathy and acute ischemic stroke.

Measurements and procedures: Participants will be randomized within 48 hours after diagnosis (maximum 96 hours after stroke onset) to standard of care (SC) alone (control group) or SC plus steroids (experimental group). SC will be harmonized among the study centres to include aspirin treatment. Patients will be assessed at 1, 3, 6 and 12 months. Magnetic imaging and angiography (MRI/MRA) will be done at 1, (3) and 6 months.

Number of Participants: 70 participants in total, 35 per treatment arm

Study duration: 48 months

Study Centre(s): International multi-centre study with approximately 20 to 30 centres

Participating countries:Switzerland, Germany, France, Austria, Great Britain & Australia

Centres in additional countries might be considered.

Statistical Considerations: The sample size is based on the comparison of the primary outcome - the change in FCASS from baseline to 1 month - between the two treatment groups. The standard deviation from 13 patients of a retrospective study was calculated. The standard deviation of the baseline and follow-up FCASS was 3.0 and 3.3, respectively. The standard deviation of the change in FCASS from baseline was 2.8. Based on the standard deviation of 2.8 and a two-sample means test, 64 patients (32 in each group) are required to detect a difference of 2.0 with a power of 80% at a two-sided alpha-level of 0.05. To account for dropouts (8%), we enlarge the sample size to 70 patients (35 in each group). The primary analysis will follow the intention-to-treat (ITT) principle, i.e. all patients will be analysed in the allocated group regardless of any protocol violations such as cross-overs. The primary outcome (change in FCASS from baseline to 1 month) as well as other secondary continuous score outcomes that are measured multiple times during follow-up (RRQ, mRS, Pediatric Stroke Outcome Measure (PSOM), VABS, modAspect) will be assessed in a repeated-measure, mixed-effects linear model.

Good Clinical Practice (GCP) Statement: This study will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH-GCP) as well as all national legal and regulatory requirements.

• Study Type: Interventional
• Enrollment (Estimated): 70
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Maja Steinlin, Dr. med.; Phone Number: +41 31 6329424; Email: maja.steinlin@insel.ch
• Study Contact Backup: Name: Leonie Steiner; Phone Number: +41316329587; Email: leonie.steiner@insel.ch

Study Locations

• Australia
  • New South Wales
    • Randwick, New South Wales, Australia, 2031
      • Not yet recruiting
      • Sydney Childrens Hospital Randwick
      • Contact: Russel Dale, Dr.
    • Westmead, New South Wales, Australia, 2145
      • Not yet recruiting
      • Sydney Childrens Hospital Network
      • Contact: Russell Dale, Dr.
  • Queensland
    • South Brisbane, Queensland, Australia, 4101
      • Not yet recruiting
      • Queensland Childrens Hospital
      • Contact: Adriane Sinclair, Dr.
  • Victoria
    • Melbourne, Victoria, Australia, 3052
      • Recruiting
      • Melbourne Childrens Hospital
      • Contact: Mark MacKay, Prof. Dr.
• Austria
  • Wien, Austria, 1090
    • Recruiting
    • Universitätsklinik für Kinder und Jugendheilkunde Wien
    • Contact: Rainer Seidl, Prof. Dr.
• France
  • Lille, France, 59037
    • Not yet recruiting
    • Hôpital Roger Salengro, CHRU de Lille
    • Contact: Laure Lacan, MD
  • Alsace
    • Strasbourg, Alsace, France, 67098
      • Not yet recruiting
      • Pediatric Neurology Strasbourg - Hautepierre University Hospital
      • Contact: Vincent Laugel, Pr, MD, PhD
  • Auvergne-Rhône-Alpes
    • Bron, Auvergne-Rhône-Alpes, France, 69677
      • Recruiting
      • Hôpital Femme Mère Enfant Lyon
      • Contact: Maryline Carneiro, Dr.
  • Ile De France
    • Le Kremlin-Bicêtre, Ile De France, France, 94275
      • Recruiting
      • Hôpitaux Universitaires Paris Sud
      • Contact: Kumaran Deiva, Dr.
    • Paris, Ile De France, France, 75743
      • Recruiting
      • Hopital Necker-Enfants Malades
      • Contact: Manoëlle Kossorotoff, Dr.
  • Provence-Alpes-Côte d'Azur
    • Marseille, Provence-Alpes-Côte d'Azur, France, 13005
      • Recruiting
      • CHU de Marseille - Hôpital de la Timone
      • Contact: Frédérique Audic-Gérard, Dr.
• Germany
  • Berlin, Germany, 13353
    • Recruiting
    • Charite-Universitatsmedizin Berlin
    • Contact: Ellen Knierim, PD Dr.
  • Baden-Württemberg
    • Freiburg, Baden-Württemberg, Germany, 79106
      • Not yet recruiting
      • Universitätsklinikum Freiburg Zentrum für Kinder- und Jugendmedizin Klinik für Neuropädiatrie und Muskelerkrankungen
      • Contact: Janbernd Kirschner, Pr., MD
      • Contact: Matthias Eckenweiler, MD
  • Baden-Wüttemberg
    • Tübingen, Baden-Wüttemberg, Germany, 72076
      • Not yet recruiting
      • Universitätsklinikum Tübingen Neuropädiatrie, Allgemeinpädiatrie, Endokrinologie, Diabetologie, Sozialpädiatrie
      • Contact: Hendrik Rosewich, Pr. MD
  • Bayern
    • München, Bayern, Germany, 80337
      • Recruiting
      • LMU Klinikum
      • Contact: Lucia Gerstl, PD Dr.
  • Nordrhein-Westfahlen
    • Düsseldorf, Nordrhein-Westfahlen, Germany, 40225
      • Recruiting
      • Universitätsklinikum Düsseldorf
      • Contact: Stefani Harmsen, Dr.
    • Münster, Nordrhein-Westfahlen, Germany, 48129
      • Recruiting
      • Universitäts Kinderklinik Münser
      • Contact: Timo Deba, Dr.
• Switzerland
  • Basel, Switzerland, 4056
    • Recruiting
    • Universitätskinderklinik beider Basel
    • Contact: Alexandre Datta, PD Dr.
  • Bern, Switzerland, 3010
    • Recruiting
    • Inselspital Bern
    • Contact: Maja Steinlin, Prof.em.Dr.
  • Geneva, Switzerland, 1211
    • Recruiting
    • Hôpitale Universitaire de Genève, Neuropediatrie, Hôpital des Enfants
    • Contact: Joel Fluss, PD Dr.
  • Luzern, Switzerland, 6000
    • Recruiting
    • Luzerner Kantonsspital, Kinderspital, Neuropädiatrie
    • Contact: Florian Bauder, Dr.
  • Saint Gallen, Switzerland, 9006
    • Recruiting
    • Stiftung ostschweizerisches Kinderspital
    • Contact: Oliver Maier, Dr.
  • Zürich, Switzerland, 8032
    • Recruiting
    • Kidnerspital Zürich
    • Contact: Annette Hackenberg, Dr.
  • Graubünden
    • Chur, Graubünden, Switzerland, 7000
      • Recruiting
      • Kantonsspital Graubünden, Departement Kinder- und Jugendmedizin
      • Contact: Reta Malär, Dr
  • Ticino
    • Bellinzona, Ticino, Switzerland, 6500
      • Recruiting
      • Ospedale Regionale di Bellinzona e Valli
      • Contact: Barbara Goeggel Simonetti, PD Dr.
  • Valais
    • Sion, Valais, Switzerland, 1950
      • Recruiting
      • Hopital du Valais
      • Contact: Nicole Faignart, Dr.
  • Vaud
    • Lausanne, Vaud, Switzerland, 1011
      • Recruiting
      • Centre Hôpitalier Universitaire Vaud (CHUV), Unité de Neurologie
      • Contact: Sébastien Lebon, Dr.
• United Kingdom
  • Bristol, United Kingdom, BS13NU
    • Recruiting
    • University Hospital Bristol
    • Contact: Adrew Mallick, Dr.
  • Cambridgeshire
    • Cambridge, Cambridgeshire, United Kingdom, CB22QQ
      • Not yet recruiting
      • Addenbrookes Hospital - Cambridge University Hospitals NHS Foundation Trust
      • Contact: Manali Chitre, MD
  • Hampshire
    • Southampton, Hampshire, United Kingdom, SO166YD
      • Recruiting
      • University Hospital Southampton
      • Contact: Jaspal Singh, Dr.
  • Lancashire
    • Manchester, Lancashire, United Kingdom, M139WL
      • Recruiting
      • Royal Manchester Children's Hospital
      • Contact: Dipak Ram, Dr.
  • Tyne And Wear
    • Newcastle, Tyne And Wear, United Kingdom, NE14LP
      • Not yet recruiting
      • Royal Victoria Infirmary
      • Contact: Rob Forsyth, Dr.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 months to 17 years (Child)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Informed consent of the legal representative of the trial participant documented by signature
2. Age > 6 months & < 18 years at time of stroke
3. Randomisation possible within 48 hours of diagnosis and maximum 96 hours after stroke onset

4. Unilateral arteriopathy according to the following criteria:

   • Newly acquired neurologic deficits

   • Specific neuroimaging (MRA) features of either

     • unilateral stenosis, or
     • unilateral vessel irregularities within the Central Nervous System (CNS)
5. Unless otherwise defined in the national addendum: Female participants age ≥ 13: Negative pregnancy test (blood or urine)

Exclusion Criteria:

1. Previous stroke
2. Known syndromal disorders, as e.g. Trisomy 21, Neurofibromatosis type 1
3. Known genetic vasculopathies as e.g. posterior fossa anomalies, hemangioma, arterial anomalies, cardiac anomalies and eye anomalies syndrome (PHACES), actin alpha 2 (ACTA II)
4. Moyamoya or sickle cell disease
5. Small vessel cerebral vasculitis (primary CNS vasculitis)
6. Bilateral arteriopathy
7. Arterial dissection(s)
8. Evidence of underlying systemic disorders, as e.g. lupus, rheumatoid problems
9. Secondary CNS angiitis due to infections (meningitis, endocarditis, borreliosis), or generalised angiitis due to rheumatic or other autoimmune problems

10. Progressive large to medium childhood primary angiitis of the CNS (cPACNS ) with 2 of the following 3 criteria:

    1. pre-existing progressive neurocognitive dysfunction
    2. bilateral MRI lesions/vessel involvement
    3. small vessel arterial stenosis
11. On steroid treatment at disease onset
12. Contraindication to steroid treatment as e.g. a congenital or acquired immunodeficiency
13. Inability to follow the procedures of the study, e.g. due to language problems
14. Participation in another interventional study within the 30 days preceding the indication stroke and during the present study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Steroids + Standard of care; Standard of care (including aspirin) and intravenous steroids, followed by oral tapering.	Drug: Prednisolone; Intravenous treatment will be immediately followed by oral tapering with Prednisolone. Oral Prednisolone, 2 weeks (week 1 and 2) Dose: 1 mg/kg/day (max 40 mg/day) Oral Prednisolone, 2 weeks (week 3 and 4) Dose: 0.5 mg/kg/day (max 20 mg/day); Other Names: Spiricort; Drug: Methylprednisolone; At the time of inclusion, intravenous Methylprednisolone for 3 days. Dose: 30 mg/kg/day (max. 1000 mg/dose); Other Names: Solu-Medrol
No Intervention: Standard of care; Standard of care (including aspirin)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Focal Cerebral Arteriopathy Severity Score (FCASS) from baseline	The FCASS is a scaling system that has been developed to improve diagnostic criteria and to better document the typical course of initial worsening followed by improvement in FCA-i (focal cerebral arteriopathy of inflammatory type). FCASS Minimum score (best outcome): 0 FCASS Maximum baseline score (worst outcome): 20 FCASS Maximum follow up score (worst outcome): 21	1 month (30 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Recovery assessed by Recovery and Recurrence Questionnaire (RRQ)	The Pediatric Recovery and Recurrence Questionnaire was specifically developed and validated for pediatric stroke patients and addresses pediatric- specific problems of manifestation of stroke and difficulties in reliable clinical examination. Minimum score (best outcome): 0 Maximum baseline score (worst outcome): 10	1, 3, 6, and 12 months
Degree of disability or dependence by modified Rankin Scale (mRS)	Minimum score (best outcome): 0 Maximum baseline score (worst outcome): 6	1, 3, 6, and 12 months
Clinical outcome by Vineland adaptive behavior scale (VABS)	The vineland adaptive behavior scale is a validated instrument to monitor cognitive and behavior problems of children by interview. (range=40-160, the higher the score the better the performance)	6 and 12 months
Change in FCASS (Focal Cerebral Arteriopathy Severity Score) from baseline	The FCASS is a scaling system that has been developed to improve diagnostic criteria and to better document the typical course of initial worsening followed by improvement in FCA-i (focal cerebral arteriopathy of inflammatory type). FCASS Minimum score (best outcome): 0 FCASS Maximum baseline score (worst outcome): 20 FCASS Maximum follow up score (worst outcome): 21	6 months
Volume of stroke	Volume of stroke will be measured by modASPECTS in diffusion-weighted MRI (DWI) and fluid-attenuated inversion recovery (FLAIR) images. Higher scores represent greater volumes, with a range of 0-30 (15 per hemisphere). modASPECTS: Modified pediatric ASPECTS ASPECTS: Alberta stroke program early CT score	baseline, 1, 3 (if imaging is available) and 6 months
Residual vasculopathy	Residual vasculopathy measured by FCASS (Focal Cerebral Arteriopathy Severity Score) The FCASS is a scaling system that has been developed to improve diagnostic criteria and to better document the typical course of initial worsening followed by improvement in FCA-i (focal cerebral arteriopathy of inflammatory type). FCASS Minimum score (best outcome): 0 FCASS Maximum baseline score (worst outcome): 20 FCASS Maximum follow up score (worst outcome): 21	6 months
Stroke recurrence after index stroke	Stroke recurrence is defined as (i) new focal neurological deficit(s) (ii) worsening of the neurological deficits by > 4 pedNIHSS points lasting for more than 24 hours with new or increased diffusion restriction at the time of recurrence (with or without FLAIR/T2 lesions) in the corresponding vascular territory, or (iii) new areas of clinically silent infarction, remote from the initial infarct (at 1 and 6 months)	1, 6 and 12 months
Stroke recurrence after index stroke in relation to the initial degree of vessel stenosis	Degree of vessel stenosis measured by change in FCASS from baseline to follow-up. Stroke recurrence will be measured as proportion in each category of vessel stenosis.	6 and 12 months
Stroke Quality of Life Measure (PSQLM)	For children between 2 -18 years quality of life will be assessed with the Pediatric Stroke Quality of Life Measure (PSQLM) (range=-10 to 10, the higher the score the better the performance)	12 month
Preschool Wechsler Intelligence Scale for Children (WISC V) / Wechsler Preschool and Primary Scale of Intelligence (WIPPSI IV)	For Children between 2 -18 years intelligence will be assessed by Preschool Wechsler Intelligence Scale for Children (WISC V) / Wechsler Preschool and Primary Scale of Intelligence (WIPPSI IV, as age appropriate) (range=40-160, the higher the score the better the performance)	12 month
Delis-Kaplan Executive Function System (D-KEFS)	Children > 8 years will undergo specific evaluation of executive function (EF). They will be assessed with the Delis-Kaplan Executive Function System (D-KEFS) Trail Making Test, Delis-Kaplan Executive Function System (D-KEFS) Color-Word-Interference Test (range=1-19, the higher the score the better the performance)	12 month
Continuous performance task (CPT-III)	Children > 8 years will undergo specific evaluation of attention. They will be assessed with the Continuous performance task (CPT-III). (range=20-80, the higher the score the better the performance)	12 month
Functional impairment outcome measured by Pediatric Stroke Outcome Measure (PSOM)	The PSOM is a measure that has been specifically developed and validated for pediatric stroke patients and addresses pediatric specific domains such as development, behavior and cognition in addition to sensory-motor and language function. PSOM Minimum score (best outcome): 0 PSOM Maximum baseline score (worst outcome): 10	1, 3, 6 and 12 months

Collaborators and Investigators

• Sponsor: Insel Gruppe AG, University Hospital Bern
• Collaborators: University of Bern
• Investigators: Principal Investigator: Maja Steinlin, Dr. med., Bern university hospital, Inselspital Bern, Kinderklinik

Publications and helpful links

General Publications

• Steinlin M, O'callaghan F, Mackay MT. Planning interventional trials in childhood arterial ischaemic stroke using a Delphi consensus process. Dev Med Child Neurol. 2017 Jul;59(7):713-718. doi: 10.1111/dmcn.13393. Epub 2017 Jan 25.

Helpful Links

• Protocol Publication

Study record dates

Study Major Dates

• Study Start (Actual): November 16, 2021
• Primary Completion (Estimated): August 1, 2025
• Study Completion (Estimated): July 1, 2026

Study Registration Dates

• First Submitted: April 15, 2021
• First Submitted That Met QC Criteria: April 29, 2021
• First Posted (Actual): May 5, 2021

Study Record Updates

• Last Update Posted (Actual): January 9, 2024
• Last Update Submitted That Met QC Criteria: January 8, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: Stroke; Pediatric; Ischemic; Steroids; Neurology; Focal; Arteriopathy; Cerebral; Unilateral
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Stroke; Physiological Effects of Drugs; Autonomic Agents; Peripheral Nervous System Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Neuroprotective Agents; Protective Agents; Prednisolone; Methylprednisolone Acetate; Methylprednisolone; Methylprednisolone Hemisuccinate; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate
• Other Study ID Numbers: 1473_PASTA; 2021-005571-39 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: It is not planned to share individual participant data to other researchers.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No